| 摘要: |
| ［摘要］ 复发性肝细胞癌（rHCC）是影响原发性肝细胞癌（HCC）初始治疗后患者长期生存的主要障碍，其5年内HCC复发率可高达70%。该文系统回顾了rHCC局部与系统治疗领域的最新进展。局部治疗包括重复肝切除术、挽救性肝移植、射频消融、微波消融、经动脉化疗栓塞、肝动脉灌注化疗、经动脉放射栓塞以及新兴治疗方式（如立体定向体部放射治疗、质子束治疗），系统治疗包括靶向治疗和免疫治疗，这些治疗显著改善了rHCC患者的预后。 |
| 关键词: 复发性肝细胞癌 局部治疗 系统治疗 联合治疗 靶向治疗 |
| DOI：10.3969/j.issn.1674-3806.2025.09.02 |
| 分类号:R 735.7 |
| 基金项目:国家重点研发计划课题（编号：2023YFB3810004） |
|
| Advances in local and systemic therapies for recurrent hepatocellular carcinoma |
|
HU Ding, HUANG Jiwei, WANG Haichuan
|
|
Department of Hepatic Surgery, West China Hospital of Sichuan University, Chengdu 610041, China
|
| Abstract: |
| ［Abstract］ Recurrent hepatocellular carcinoma(rHCC) is a major obstacle affecting the long-term survival of primary hepatocellular carcinoma(HCC) patients after receiving initial treatment for HCC, and their recurrence rate of HCC reaches as high as 70% within 5 years. This paper systematically reviews the latest progress in the field of local and systemic therapies for rHCC. Local therapies include repeat hepatectomy, salvage liver transplantation, radiofrequency ablation, microwave ablation, transarterial chemoembolization, hepatic arterial infusion chemotherapy, transarterial radioembolization as well as newly-developing therapies(such as stereotactic body radiotherapy and proton beam therapy). Systemic therapies include targeted therapy and immunotherapy. These therapies significantly improve the prognosis of patients with rHCC. |
| Key words: Recurrent hepatocellular carcinoma(rHCC) Local therapy Systemic therapy Combined therapy Targeted therapy |
